Načítá se...
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine
BACKGROUND: The treatment of ulcerative colitis (UC) can place a substantial financial burden on healthcare systems. The anti-inflammatory compound 5-aminosalicylic acid (5-ASA; mesalazine) is the recommended first-line treatment for patients with UC. In this analysis, the incremental cost effective...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2011
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3146407/ https://ncbi.nlm.nih.gov/pubmed/21729262 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1472-6963-11-157 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|